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tient or study characteristics. Studies on other dialysis tech-
niques showed mixed results regarding the AVP course. The 
eight studies that addressed the relation between intradia-
lytic hypotension and AVP also showed inconsistent results. 
 Key Messages: Plasma AVP levels are higher in dialysis pa-
tients compared with healthy controls, but show little or no 
increase during HD. The lack of a rise in AVP levels during HD 
may be pathophysiologically involved in the onset of intra-
dialytic hypotension, but firm conclusions are not possible 
from our review of the literature.  © 2014 S. Karger AG, Basel
 Introduction
 Intradialytic hypotension is a serious complication of 
hemodialysis (HD) and is estimated to occur in about 20–
30% of HD treatments  [1, 2] . Symptoms of intradialytic 
hypotension vary from mild, transient symptoms, such as 
muscle cramps, nausea and dizziness, to serious compli-
cations like cardiac ischemia and arrhythmias, and cere-
brovascular events  [1, 3] . Intradialytic hypotension is also 
associated with an increased mortality  [4] . Intradialytic 
hypotension occurs when cardiovascular compensatory 
mechanisms are unable to compensate for the decrease in 
blood volume during HD  [1, 5, 6] . Important physiologic 
 Key Words
 Arginine vasopressin · Hemodialysis · Intradialytic 
hypotension
 Abstract
 Background: Intradialytic hypotension is a common compli-
cation of hemodialysis (HD). Some studies have suggested 
that inadequate arginine vasopressin (AVP) increase could 
play a role in the pathogenesis of intradialytic hypotension. 
However, AVP levels during HD and its relation to hypoten-
sion has never been systematically studied.  Summary: 
PubMed and Embase were searched (1970–2013, search 
terms ‘vasopressin’ and ‘hemodialysis’) for studies reporting 
on AVP levels during standard HD or other dialysis tech-
niques. Observational studies reporting on AVP levels pre- 
and postdialysis were additionally included in a meta-analy-
sis. Thirty-seven studies were included in the systematic lit-
erature review, of which 26 studies were eligible for 
meta-analysis. The main findings were that pretreatment 
AVP levels were higher in dialysis patients compared with 
healthy controls (6.4 ± 3.5 vs. 2.5 ± 1.3 pg/ml, p = 0.003) and 
that plasma AVP levels showed little or no increase during 
HD (from 7.0 ± 4.9 to 8.8 ± 9.3, p = 0.433) . Significant hetero-
geneity was found between studies. Meta-regression analy-
sis revealed no significant associations between AVP and pa-
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compensatory mechanisms for maintaining blood pres-
sure during HD are vascular refill from interstitial tissue, 
an increase in heart rate and contractility, and arterial and 
venous vasoconstriction  [1, 7] . These mechanisms are 
predominantly regulated by the sympathetic nervous sys-
tem and the renin-angiotensin system. Although dialysis 
patients generally have an overactive sympathetic ner-
vous system and renin-angiotensin system  [8–12] , the in-
crease in peripheral resistance is insufficient to prevent 
intradialytic hypotension in many patients  [13, 14] . As a 
consequence, the role of the vasoconstrictor arginine va-
sopressin (AVP) for maintaining blood pressure may be-
come increasingly important  [15–17] .
 Physiology of AVP
 AVP, also known as the antidiuretic hormone, is a 
1-kDa nonapeptide, synthesized in the supraoptic and 
paraventricular nuclei of the hypothalamus and stored in 
secretory granules in the posterior pituitary gland. The 
normal plasma AVP concentration in a fasted and hy-
drated person is below 4 pg/ml  [18–21] . The plasma half-
life of AVP is about 5–35 min and it is rapidly metabo-
lized by liver and kidney vasopressinases  [19, 20, 22] .
 The most powerful stimuli for AVP release are hyper-
osmolality, which acts through the osmoreceptors, and 
hypotension and hypovolemia, which both act through 
the baroreceptors, i.e. the baroreceptor reflex ( fig. 1 )  [18–
20] . Under normal physiological conditions, changes in 
plasma osmolality are the main regulator of AVP release 
 [20, 23–26] . In comparison with a rise in plasma osmolal-
ity, decreases in plasma volume and blood pressure are 
less potent stimuli for AVP release, but the magnitude of 
the potential AVP response to hypovolemia and hypoten-
sion exceeds the potential AVP response elicited by an 
increase in plasma osmolality  [23, 26] .
 Importantly, the baroreceptor and osmoreceptor 
pathways do not function in isolation since a reduction in 
plasma volume increases the sensitivity of the osmore-
ceptors  [26] . AVP release is also stimulated by nausea and 
pain via central nervous input  [19, 26] .
 AVP exerts its physiological actions by binding to 
three distinct receptors. Stimulation of V1 receptors 
causes vasoconstriction of the systemic arteries and ve-
nous capacitance vessels  [20, 27] , whereas V2 receptors 
mediate antidiuretic activity. There are also V3 pituitary 
receptors, formerly known as V1b receptors, of which 
the function is less well understood, but appear to be in-
volved in the release of adrenocorticotropic hormone 
 [18, 19] . V1 receptors are mainly found on vascular 
smooth muscle of the systemic, renal, splanchnic and 
coronary circulation  [23, 28] . The degree of vasocon-
striction depends on the vascular bed. AVP is a potent 
vasoconstrictor, especially in skin and skeleton muscle, 
and to a lesser extent in mesenteric, coronary and cere-
bral circulations  [19, 20, 22] . Thus, besides regulating the 
body’s water balance, AVP has the ability to increase 
blood pressure through systemic vasoconstriction  [19, 
20] . The effect of AVP is normally overshadowed by oth-
er blood pressure-regulating systems like the sympathet-
ic nervous system and renin-angiotensin system  [16, 29] . 
However, AVP becomes increasingly important in main-
taining hemodynamic stability when blood pressure is 
endangered and/or during hypovolemia  [15, 20, 22, 30–
33] .
 Stimuli for AVP Release during HD
 HD with ultrafiltration inevitably leads to reductions 
in blood volume and blood pressure, both powerful 
stimuli for AVP release, in the vast majority of patients. 
Other stimuli for the release of AVP during HD include 
nausea and pain related to puncture of the fistula. The 
effect of conventional HD on plasma osmolality is not 
well delineated, with some studies reporting no change 











 Fig. 1. Major pathways leading to AVP release and a subsequent 
rise in blood pressure in hemodialysis patients. 
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lality  [15, 35–44] .  Table 1 summarizes the theoretical ef-
fects of HD on AVP release. It is clear that the stimuli 
for AVP release prevail. Therefore, one would theoreti-
cally expect a significant rise in AVP levels during HD. 
It seems, however, that plasma AVP levels show little or 
no increase during HD and it could, therefore, well be 
that an inadequate rise of AVP plays an important role 
in the pathogenesis of intradialytic hypotension  [24, 33] . 
However, since most studies were small-scale and un-
derpowered, the true effect of HD on AVP levels may be 
underestimated.
 In this systematic literature review, we first summa-
rize the available observational studies on plasma AVP 
levels in standard HD and other dialysis techniques. De-
tails on study selection, data extraction and statistical 
analysis are provided in the online supplementary mate-
rial (item S1; for all online suppl. material, see www.
karger.com/doi/10.1159/000358203). We specifically in-
vestigated: (1) whether AVP levels before dialysis differ 
from those in healthy controls, (2) whether standard HD 
is associated with a change in AVP levels and (3) wheth-
er there is a relation between the intradialytic change in 
AVP levels and intradialytic hypotension. Next, we dis-
cuss possible underlying mechanisms for inadequate 
AVP increase. Finally, we address whether intradialytic 
hypotension may be prevented by AVP-based interven-
tions, such as modification of the HD prescription to 
stimulate endogenous AVP release and the administra-
tion of AVP analogues.
 Results of the Systematic Literature Review and 
Meta-Analysis
 Search Results and Study Characteristics
 Figure 2 shows the flow diagram of our search strategy. 
One hundred and two studies were identified by the ini-
tial search, 66 in PubMed and 36 in Embase. Thirty-one 
of these articles were duplicate publications and 21 arti-
cles were excluded on the basis of screening of the ab-
stract. A total of 50 full-text articles were assessed, of 
which 13 were excluded since they did not meet the eligi-
bility criteria. Online supplementary item S2 provides an 
overview of the excluded articles. Thirty-seven articles 
were included in the systematic review (online suppl. ta-
ble S1). Of these, 26 studies provided information on 
plasma AVP levels before and after standard HD (defined 
as HD with constant ultrafiltration rate and dialysate con-
ductivity) and these studies were included in the meta-
analysis of the effect of standard HD on AVP levels. On-
line supplementary table S2 provides the key features of 
the studies included in the meta-analysis.
 Table 1.  Theoretical stimuli for AVP release during dialysis
 Stimulus
for AVP release 
 Physiological effect in healthy individuals  Stimulus for AVP release during HD  Expected effect 
on AVP levels 
with HD 
 Hypotension   Small reductions in blood pressure (5  –  10% from 
baseline) usually have little effect on plasma AVP 
levels [20], but a fall of >10% causes a significant 
rise in plasma AVP levels [23] 
 The fall in systolic blood pressure during HD 
averaged 22 mm Hg (–14% compared with 
predialysis systolic blood pressure) in several 
studies [33, 34, 38, 40, 44, 55] 
 ++ 
 Hypovolemia  Plasma AVP levels generally increase when blood 
volume decreases 8  –  10% or more [20, 26] 
 The fall in relative blood volume during HD 
averaged 12% in four studies [34, 35, 37, 55] 
 ++ 
 Increase in 
osmolality 
 Osmoregulation is a sensitive system and small 
increases in osmolality cause a significant rise in 
AVP levels [20, 23] 
 Several studies reported no change [29, 34] or 
a decrease [15, 35  –  44] in plasma osmolality 
during HD 
 – 
 Nausea  Nausea stimulates AVP release [19, 21, 22, 26, 75]  One study showed that plasma AVP levels 
rose markedly in hypotension-prone patients 
experiencing nausea, as opposed to patients 
who did not experience nausea [29] 
 + 
 Pain   Pain acutely stimulates the release of AVP [19, 22, 
26] 
 Puncture of the arteriovenous fistula can be 
painful and theoretically stimulates AVP 
release 
 + 
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 Plasma Vasopressin Levels in Dialysis Patients and 
Healthy Individuals
 Plasma AVP levels were measured in both HD patients 
and healthy controls in a total of 7 studies. Despite con-
siderable variation, the studies in which healthy controls 
were included  [24, 25, 35, 37, 45–47] uniformly showed 
that pretreatment plasma AVP levels were more than 
twice as high in dialysis patients compared with healthy 
controls (6.4 ± 3.5 vs. 2.5 ± 1.3 pg/ml, p = 0.003) in an in-
direct comparison ( fig. 3 a) as well as in a direct compari-
son ( fig. 3 b).
 Plasma AVP levels in patients varied widely, with some 
studies reporting pre-HD plasma AVP levels above the 
concentration regarded as the upper level of normal of 4 
pg/ml  [2, 16, 24, 25, 35, 37–41, 45–54] , while others found 
pretreatment plasma AVP levels around or below 4 pg/ml 
 [32–34, 43, 44, 55–57] ( fig. 3 a).The variation in pretreat-
ment plasma AVP levels might be due to analytical varia-
tion resulting from the use of different assays. Other pos-
sible factors include differences in patient characteristics 
between studies, e.g. the percentage of included patients 
with diabetes mellitus, and predialysis blood pressure, hy-
dration status, plasma osmolality and pain related to can-
nulation of the fistula. Most of the included studies, how-
ever, lack description of these factors. This precludes the 
use of random effect meta-analysis and meta-regression 
analysis to consider between-study variability and to as-
sess factors that could explain the differences in plasma 
AVP levels within HD patients and between HD patients 
and healthy individuals, respectively.
 Effect of Dialysis on Plasma AVP Levels
 Thirty-seven studies, comprising 681 patients, were in-
cluded in the systematic literature review. Twenty-six of 
these studies, comprising 496 patients, were eligible for 
the meta-analysis since these studies reported the mean 
and standard deviation of plasma AVP levels before and 
after standard HD. Several studies observed a significant 
increase in plasma AVP levels during HD  [15, 16, 29, 38, 
52, 53, 57] , whereas the other studies did not  [32–37, 39–
44, 46, 49–51, 54–56, 58] . Overall, plasma AVP levels 
showed little or no increase during standard HD (7.0 ± 4.9 
and 8.8 ± 9.3 pg/ml for pre- and post-HD, respectively; 
p = 0.433) .  These results were confirmed by meta-analysis 
(mean difference 0.13 pg/ml, 95% CI –0.82 to 1.07;  fig. 4 ). 
However, interpretation of the overall results should be 
done with caution, considering significant between-study 
heterogeneity (χ 2  = 159.05; p < 0.001; I 2  = 84%). This 
might be explained by differences in characteristics of the 
included patients and differences in study design.
 When a meta-regression analysis was performed, in-
vestigating whether patient characteristics (i.e. age, gen-
der, change in blood pressure and plasma osmolality dur-
ing HD) or study design (i.e. treatment duration and di-
alysate sodium used) were associated with the change in 
AVP during HD, no significant explanatory associations 
were found (all p > 0.10).
 When looking into the studied patient subpopulations 
in more detail, plasma AVP levels did not change signifi-
cantly during standard HD in the vast majority of hypo-
tension-prone patients  [29, 34, 55] or in normotensive or 
hypertensive patients  [32, 37, 44, 49, 54, 59] . Other studies 
did not specify whether their patient populations were hy-
potension-prone or not, but also found no change, or even 
a decrease, in plasma AVP levels during HD, irrespective 
of whether blood pressure remained stable  [41, 43, 50, 51, 
58] or decreased during HD  [33, 35, 36, 39, 40, 46] .
 Other Dialysis Techniques
 Studies that used specific dialysis techniques, like ul-
trafiltration-only (UF-only) and HD with sodium profil-
ing, may give better insight into the physiological re-
102 records identified by
database searches
(PubMed and Embase)
71 records after removal of duplicates
71 records screened
21 records excluded
(content not relevant after
reading the abstract)
13 full-text articles excluded
(11 did not meet eligibility
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 Fig. 2. Search strategy of the systematic literature review. 
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 Study group  Subjects, n 
 Healthy controls 
 Cernaro, 2012 [24]  30 
 Zoccali, 1991 [47]  45 
 Martinez-Vea, 1985 [46]  35 
 Iitake, 1985 [37] 5 
 Nord, 1979 [25] 6 
 Hammer, 1979 [45]  10 
 Shimamoto, 1977 [35]  33 
 Dialysis patients 
 Cernaro, 2012 [24]  50 
 Ettema, 2012 [34]  15 
 van der Zee, 2007 [33]  10 
 Katzarski, 1999 [44]  16 
 Witkowicz, 1999 [53]  39 
 Uusimaa, 1999 [51]  12 
 Nakayama, 1998 [16] 5 
 Iimura, 1996 [57]  13 
 Friess, 1995 [29]  23 
 Grzeszczak, 1995 [52]  30 
 Hegbrant, 1994 [56]  10 
 Hegbrant, 1994 [43]  10 
 Odar-Cederlöf, 1993 [2]  12 
 Hegbrant, 1993 [59]  11 
 Hegbrant, 1993 [42]  11 
 Heintz, 1993 [55]  13 
 Yamada, 1993 [15]  12 
 Os, 1993 [40]  13 
 Graziani, 1993 [49]  13 
 Zoccali, 1991 [47]  14 
 Heidbreder, 1990 [50]  51 
 Elias, 1989 [58]  10 
 Andersson, 1988 [41]  10 
 Papadoliopoulou, 1987 [32]  18 
 Larochelle, 1987 [38]  38 
 Jawadi, 1986 [39]  25 
 Martinez-Vea, 1985 [46]  23 
 Iitake, 1985 [37]  40 
 Fasanella d’Amore, 1985 [48] 6 
 Wizemann, 1983 [54] 6 
 Horký, 1979 [36]  25 
 Nord, 1979 [25]  10 
 Hammer, 1979 [45] 7 
 Shimamoto, 1977 [35]  28 
Pretreatment plasma AVP levels (pg/ml)
0 10 20 30
 Fig. 3.  a Plasma AVP levels (pg/ml) in dialysis patients pretreatment and healthy controls that were included in 
the same study as dialysis patients. The vertical dotted line indicates a plasma AVP level of 4 pg/ml;  ◆ denotes 
mean ± SD in healthy subjects;  ◼ denotes mean ± SD in patients;  ◇ denotes mean in healthy subjects and in pa-
tients. Studies are ordered by year of publication. 
 (For fig. 3b, see next page.) 
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sponse of AVP to various aspects of the dialysis treat-
ment since the volumetric and osmotic stimuli of AVP 
release can be (more or less) studied in isolation. Four 
studies used UF-only. The course of plasma AVP levels 
in response to the course of blood pressure in these stud-
ies appeared to be in line with the physiological expecta-
tion: a stable blood pressure was associated with un-
changed AVP levels  [45, 58] while a decrease in blood 
pressure was accompanied by increases in plasma AVP 
levels  [46, 47] .
 Studies in which UF-only was preceded or followed by 
isovolumic HD showed divergent results regarding the 
course of AVP  [2, 39, 40, 48, 59] . It is beyond the scope of 
this article to discuss these studies in detail. Studies in 
which HD with intermittent ultrafiltration was applied 
showed that mean plasma AVP levels changed in the op-
posite direction to changes in blood volume  [31, 60] , al-
though plasma AVP levels did not closely follow changes 
in blood volume in the individual patient  [60] . 
 One group investigated plasma AVP level responses to 
HD with varying dialysate sodium concentrations and 
varying ultrafiltration rates during multiple treatment 
sessions. Again, inconsistent results were found  [25] . One 
study investigated the effect of the biofeedback system 
Hemocontrol on AVP levels. This technique continuous-
ly varies dialysate sodium concentrations and ultrafiltra-
tion rates in response to the patient’s relative blood vol-
ume level  [61, 62] . An initial increase in plasma osmolal-
ity and a prominent fall in blood volume coincided with 
higher plasma AVP levels during the first hour of Hemo-
control treatment in comparison with standard HD  [34] . 
However, AVP levels did not differ between standard HD 
and Hemocontrol HD at the end of the treatment.
 Finally, two studies looked into plasma AVP levels 
during hemodiafiltration, also with mixed results. Blood 
pressure and plasma osmolality decreased in both studies, 
while plasma AVP levels decreased in one study  [24] and 
rose in another study  [54] .
 Plasma Vasopressin and Intradialytic Hypotension
 Some studies suggested a possible role for deficient or 
inadequate AVP increase during HD in the pathogenesis 
of intradialytic hypotension  [16, 24, 33] . Eight studies in-
vestigated plasma AVP levels in relation to intradialytic 
hypotension. These studies showed mixed results, but it 
is important to note that plasma AVP levels were gener-
ally measured after intradialytic hypotension instead of 
during intradialytic hypotension. In addition, in these 
eight studies a total of five different definitions of intra-
dialytic hypotension were used  [21, 29, 34, 47, 60] , where-
 Study or 
subgroups 
 Patients  Healthy controls Weight, 
 % 
 Mean difference  Mean difference 
 mean  SD total  mean   SD total  IV, ran dom, 95% CI  year  IV, random, 95% CI 
 Shimamoto [35] 6.7  2.1 28  4.3  1.1 33 15.5 2.40 [1.54, 3.26]  1977 
 Hammer [45] 5.1  1.6 7  2.7  0.9 10 14.2 2.40 [1.09, 3.71]  1979 
 Nord [25] 4.9  1.8 10  1  1.6 6 12.9 3.90 [2.20, 5.60]  1979 
 Iitake [37]  14.2  6.2 40  3.9  0.7 5 11.7  10.30 [8.28, 12.32]  1985 
 Martinez-Vea [46] 5.1  1.3 23  2.4  4.3 35 13.5 2.70 [1.18, 4.22]  1985 
 Zoccali [47] 4.6  1.5 14  1.1  0.5 45 15.7 3.50 [2.70, 4.30]  1991 
 Cernaro [24] 4.3  1.1 50  2.3  0.3 30 16.5 2.00 [1.68, 2.32]  2012 
 Total (95% CI)  172  164  100 3.67 [2.40, 4.93] 
 Heterogeneity: τ2 = 2.49; χ2 = 75.18, d.f. = 6 (p < 0.00001); I2 = 92% 
 Test for overall effect: Z = 5.68 (p < 0.00001) 
–10 0–5 5 10
 Fig. 3.  b Absolute differences in AVP levels (pg/ml) between HD patients before treatment and healthy controls 
in studies that provided a within-study comparison of plasma AVP levels in both groups. Studies are ordered by 
year of publication. Mean differences are pooled using the random-effects model and shown on a scale from –10 
to 10 pg/ml. CI = Confidence interval; IV = inverse variance. 
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as in three studies no definition was provided at all  [2, 45, 
48] . In some of these studies it was found that plasma 
AVP levels were higher after intradialytic hypotension 
had occurred  [45, 48, 60] , whereas others found no differ-
ence in plasma AVP levels between patients with and 
without intradialytic hypotension  [47] , or only observed 
higher AVP levels when intradialytic hypotension was ac-
companied by nausea  [29] .
 In only two studies was blood sampling performed at 
the moment that intradialytic hypotension actually oc-
curred  [21, 29] . In one of these studies, Rho et al.  [21] 
showed that plasma AVP levels did not differ between 
patients who did and those who did not experience intra-
dialytic hypotension. All in all, at present no clear conclu-
sion can be made about whether an inadequate rise in 
AVP levels has a role in the pathophysiology of intradia-
lytic hypotension.
 Potential Mechanism of the Relative AVP Deficiency 
during HD
 Presently, there is no definite answer to why AVP lev-
els do not increase during HD despite significant decreas-
es in blood volume and blood pressure. However, several 
mechanisms can be considered.
 Study or subgroup  Weight, 
% 
 Mean difference  Mean difference 
 IV,  random, 95% CI  year  IV, random, 95% CI 
 Shimamoto [35] 4.9  –0.10 [–1.49, 1.29]  1977 
 Horký [36] 5.2  –2.30 [–3.19, –1.41]  1979 
 Wizeman [54] 4.2  –4.30 [–6.26, –1.74]  1983 
 Martinez-Vea [46] 5.0  –0.70 [–1.97, 0.57]  1985 
 Iitake [37] 4.2  –6.00 [–8.27, –3.73]  1985 
 Jawadi [39] 5.0  –3.00 [–4.25, –1.75]  1986 
 Larochelle [38] 3.4 2.90 [–0.32, 6.12]  1987 
 Papadoliopoulou [32] 4.9  –0.80 [–2.15, 0.55]  1987 
 Andersson [41] 2.7 1.10 [–2.98, 5.18]  1988 
 Elias [58] 3.6 0.10 [–2.79, 2.99]  1989 
 Heidbreder [50] 3.9  –0.20 [–2.82, 2.42]  1990 
 Hegbrant [42] 3.9 0.00 [–2.59, 2.59]  1993 
 Yamada [15] 4.3 0.60 [–1.53, 2.73]  1993 
 Os [40] 4.7  –3.00 [–4.61, –1.39]  1993 
 Graziani [49] 3.4 5.00 [1.81, 8.19]  1993 
 Hegbrant [43] 3.7 0.50 [–2.34, 3.34]  1994 
 Hegbrant [56] 4.5  –0.50 [–2.34, 1.34]  1994 
 Grzeszczak [52] 4.4 5.60 [3.56, 7.64]  1995 
 Friess [29] 0.1  35.90 [2.93, 68.87]  1995 
 Iimura [57] 4.2 2.00 [–0.18, 4.18]  1996 
 Nakayama [16] 1.3 2.10 [–4.97, 9.17]  1998 
 Uusimaa [51] 1.4 4.10 [–2.76, 10.96]  1999 
 Witkowicz [53] 3.2 5.40 [1.95, 8.85]  1999 
 Katzarski [44] 5.2 0.60 [–0.32, 1.52]  1999 
 van der Zee [33] 3.4 1.90 [–1.32, 5.12]  2007 
 Ettema [34] 5.3 0.23 [–0.58, 1.04]  2012 
 Total  (95%  CI)  100.0 0.13  [–0.82,  1.07] 
 Heterogeneity: τ 2  = 4.23; χ 2  = 159.05, d.f. = 25 (p < 0.00001); I 2  = 84% 
 Test for overall effect: Z = 0.26 (p = 0.79) 
post-HD lower than pre-HD post-HD higher than pre-HD
–5 0 5–10 10
 Fig. 4. Absolute changes in plasma AVP (pg/ml) levels from pre- to post-HD. Studies are ordered by year of pub-
lication. Mean differences are pooled using the random-effects model and shown on a scale from –10 to 10 pg/
ml. CI = Confidence interval; IV = inverse variance. 
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 First, since AVP secretion is under control of the baro-
reflex arc, autonomic dysfunction could impair the release 
of AVP, as has been suggested by several groups  [21, 24, 
33] . Dysfunction of the autonomic nervous system is com-
mon in patients on HD  [47, 63, 64] . However, literature 
on AVP kinetics in relation to autonomic impairment in 
HD patients is scarce and conflicting. One group suggest-
ed that a defect in the afferent limb of the baroreceptor 
reflex arc might be responsible for inadequate AVP stim-
ulation in some patients with recurrent intradialytic hy-
potension  [29] whereas another group concluded that the 
reflex AVP secretion was unaffected in patients on HD, 
even in the presence of autonomic dysfunction  [47] . 
 Second, it has been suggested that an increase in the 
production of nitric oxide during HD might impair AVP 
release  [33] . Animal studies indeed suggest an inhibitory 
effect of nitric oxide on AVP release  [65, 66] . However, 
this concerns a relation at the hypothalamic-pituitary lev-
el. To our knowledge, it has not been studied whether 
peripherally released nitric oxide is also able to inhibit 
AVP release from the pituitary gland. Nitric oxide, how-
ever, may inhibit sympathetic activity in patients experi-
encing intradialytic hypotension  [67] and, consequently, 
could attenuate AVP secretion.
 Third, it has been suggested that increases in plasma 
AVP levels may be inadequate due to removal of AVP by 
HD, considering its molecular size of only 1 kDa  [68] . At 
present, however, no clear conclusion can be drawn on 
whether AVP is removed in substantial amounts by HD. 
One study has reported similar plasma AVP concentra-
tions in the in- and outgoing blood before and after the 
dialyzer during HD  [69] , suggesting that there is no sig-
nificant clearance of AVP, whereas two other studies de-
tected AVP in the ultrafiltrate  [37, 70] , suggesting that 
there is at least some removal of AVP by HD. Systematic 
data on AVP clearance by dialyzers are lacking.
 Effect of Administration of Exogenous AVP on 
Hemodynamic Stability during HD
 Four groups have investigated the effect of administra-
tion of AVP or synthetic AVP analogues on hemodynam-
ic stability during HD  [33, 71–73] (online suppl. table S3). 
Studies using the AVP analogues lysine vasopressin and 
desmopressin intranasally in hypotension-prone patients 
demonstrated that the incidence of intradialytic hypoten-
sion (defined as a decrease in systolic blood pressure >10 
mm Hg  [71] and a decrease in MAP to <70 mm Hg after 
treatment initiation  [73] ) decreased significantly in com-
parison with placebo  [71, 73] . In addition, the total vol-
ume of intravenous fluid administration was significant-
ly lower with lysine vasopressin compared with placebo 
 [73] and post-HD blood pressure was higher when des-
mopressin was used before HD compared with placebo 
 [71] . When AVP was administered intravenously, an as-
sociation between an improved intradialytic blood pres-
sure stability  [33] and a significantly increased intradia-
lytic blood pressure  [72] were found.
 Currently available AVP analogues for clinical practice 
are desmopressin and terlipressin. Terlipressin is a nonse-
lective AVP analogue and it has a slightly greater affinity 
for V1 receptors than AVP  [20] . Since terlipressin predom-
inantly has vasoconstrictive effects, this drug may be pref-
erable for the prevention of intradialytic hypotension over 
desmopressin, which exerts mainly antidiuretic actions. 
Terlipressin itself is inactive and is gradually converted 
into the active metabolite lysine vasopressin, with an effect 
half-life of 6 h  [19, 20] and a peak concentration after 60–
120 min. Administration of vasopressin to generate a plas-
ma concentration of 20–30 pg/ml was found to produce a 
pressor response with minimal organ hypoperfusion in pa-
tients without renal disease  [19] . Before exogenous AVP 
administration is applicable in routine clinical practice, 
optimal timing and dosage of AVP analogues and the safe-
ty of their repetitive administration should be determined. 
 Knowledge Gaps and Future Research
 Although our systematic review provides insight into 
the potential role of vasopressin in intradialytic hypoten-
sion, a number of questions remain. First, it is uncertain 
whether post-HD AVP levels are a good representation of 
the intradialytic course of AVP. Future studies should, 
therefore, investigate plasma AVP levels during HD in 
relation to pre- and postdialysis levels. Second, it should 
be investigated whether AVP is removed by the artificial 
kidney during HD. Third, a firm conclusion on the rela-
tionship between AVP levels and intradialytic hypoten-
sion is hampered by the use of varying definitions of in-
tradialytic hypotension  [21, 29, 34, 47, 60] . Future studies 
should therefore use a uniform definition of intradialytic 
hypotension, such as the one provided by the European 
Best Practice Guidelines  [74] . However, the data from in-
tervention studies showing that exogenous AVP admin-
istration results in improved hemodynamic stability indi-
rectly supports the belief that the lack of a rise of AVP 
could be pathophysiologically involved in the develop-
ment of intradialytic hypotension. 
 Ettema  /Zittema  /Kuipers  /Gansevoort  /
Vart  /de Jong  /Westerhuis  /Franssen  
 




 This systematic literature review shows that plasma 
AVP levels are higher in dialysis patients compared with 
healthy individuals, but do not rise during HD despite 
decreases in blood pressure and blood volume, which are 
physiological stimuli for AVP secretion. Potential under-
lying mechanisms for the lack of an increase in AVP lev-
els during dialysis include dysfunction of (components 
of) the baroreceptor arc, an inhibitory effect of nitric ox-
ide on the sympathetic nervous system and removal by 
dialysis. The lack of a rise in AVP levels during HD may 
play a role in the onset of intradialytic hypotension and 
administration of AVP or an AVP analogue might ben-
efit HD patients.
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